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The cause and pathophysiology of mood and psychotic dis-
orders, including unipolar depression, bipolar disorder, and
schizophrenia, is variable. Several scenarios have been pro-
posed to explain the development of psychoses, one of
which is mitochondrial dysfunction (mitochondrial mood
and psychotic disorders) [1,2]. Impaired mitochondrial
pathways, which may be associated with mood and psych-
otic disorders, include the respiratory chain (Figure 1) [1,3],
the pyruvate-dehydrogenase complex, the 2-ketoglutarate
dehydrogenase [4], and the polyol pathway [5]. Disturbance
of the respiratory chain is the most frequent cause of mito-
chondrial mood and psychotic disorders. Mood and psych-
otic disorders in patients with mitochondrial disorders may
be the sole manifestation, or one among other manifesta-
tions, of a mitochondrial disorder. Mood and psychotic dis-
orders may be the dominant feature of the phenotype or a
collateral finding, and may occur in syndromic as well as
non-syndromic [5,6] mitochondrial disorders.
A recent study, published in this journal [1], aimed to as-
sess psychiatric abnormalities in mitochondrial disorders
with a proven mtDNA defect [1]. Twelve patients had a syn-
dromic mitochondrial disorder (mitochondrial encephalo-
myopathy, lactic acidosis, and stroke-like episodes (MELAS),
myoclonic epilepsy with ragged red fibers (MERRF), neur-
opathy, ataxia, and retinitis pigmentosa (NARP), progressive
external ophthalmoplegia (PEO), Kearns-Sayre syndrome
(KSS)) and seven patients had a non-syndromic mitochon-
drial disorder. The frequency of psychiatric diagnoses among
these patients was reported to be 47% [1]. Psychiatric condi-
tions may be even more common in other studies and in-
clude major depression, agoraphobia and/or panic disorder,
generalized anxiety disorder, social anxiety disorder, or psych-
otic syndromes [7]. The medication these patients took at in-
clusion was provided for only nine patients. Among these
drugs, however, several are reported to be mitochondrion-
toxic. Two patients were medicated with valproic acid, twoCorrespondence: fifigs1@yahoo.de
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reproduction in any medium, provided the orwith quetiapine, and one each with carbamazepine, atorvas-
tatin, mirtazepine, metformin, and trazodone [1].
The study did not address whether, and to what degree,
anti-psychotic or other medication may worsen the under-
lying defect due to mitochondrion-toxicity of the applied
medication [1]. This is important since deterioration of the
clinical presentation may not only be due to worsening of the
underlying metabolic defect, but also due to mitochondrion-
toxicity of the applied anti-psychotic medication. Since a
number of mitochondrion-toxic drugs are used to treat mood
and psychotic disorders and may worsen the underlying
metabolic defect, it is essential to exclude a mitochondrial
metabolic defect before applying these agents. In addition to
anti-psychotic drugs, patients with mitochondrial disorders
and mood and psychotic disorders may also take other drugs,
which may be mitochondrion-toxic. For a number of anti-
psychotic and other drugs, however, it is not well known
whether they are truly mitochondrion-toxic, neutral or, rather,
mitochondrion-protective.
Some agents described in the study have been reported to
cause severe, sometimes even fatal, adverse reactions, such
as valproic acid, which may cause irreversible liver failure,
particularly in patients carrying POLG1 mutations [8].
Other drugs may be mitochondrion-toxic without obvious
major clinical side effects, such as atorvastatin, which
reduces the coenzyme-Q content and generally decreases
mitochondrial functions [9], mirtazepine, which decreases
complex-I activity [10], metformin, which inhibits complex-I
of the respiratory chain [11], quetiapine, which inhibits
complex-I [12], or trazodone, which collapses the mitochon-
drial membrane potential and imposes oxidative stress [13].
Antipsychotic medication may not only affect the function of
respiratory chain complexes, but also activity of the
pyruvate-dehydrogenase complex [14]. Some of the drugs
applied may also have a protective effect on mitochondrial
functions, such as vinpocetine [15], trimetazidine [16], sertra-
line [17], levetiracetam [18], bisoprolol [19], or enalapril [20].
Based on these considerations, it is advisable that patients
with mitochondrial disorders receive special attention when
treated with agents whose effects on mitochondria areThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Eukaryotic respiratory chain located at the inner mitochondrial membrane. While electrons are transported horizontally along all
respiratory complexes, protons are vertically pumped into the inter-membrane space by complexes I, III, and IV. Via complex V protons are
pumped into the matrix to react with the electrons to ATP and H2O (from Wikipedia).
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psychotic compounds be mitochondrion-toxic but so could
be a number of other agents used in the daily routine. Since
mitochondrial disorders are gaining increasing attention and
thus being diagnosed more often, care has to be taken when
selecting drugs for these patients. Since some patients may
be highly sensitive to various compounds, these patients
should be treated like patients with myasthenia gravis, who
also react to contra-indicated medication with severe, occa-
sionally fatal side-effects. Animal and human studies on the
compatibility of agents with already disturbed mitochondrial
metabolism, however, are required to find out which of the
drugs are tolerated by patients with mitochondrial disorders
and which are toxic to them.
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